Neurodegenerative and other central nervous system disorders are some of the hardest to develop treatments for due to our limited understanding of the brain. But Cerevance developed a new technology capable of profiling neuronal and glial cell populations at depths not previously possible, which is allowing the clinical-stage pharmaceutical company to identify potential drug targets in specific cell types critical to circuits disrupted by disease. By selectively targeting those cell types, the company hopes to develop more effective and safer therapeutics for CNS diseases. PM360 spoke with CEO Brad Margus about the company’s journey and its potential impact on the future of drug development.